Dev Chatterjee, Raghavendra Kamath, Sohini Das &Amp;Amp; Avishek Rakshit

Stories by Dev Chatterjee, Raghavendra Kamath, Sohini Das &Amp;Amp; Avishek Rakshit

Covid: How Pfizer plans to resolve cold storage issues in India

Covid: How Pfizer plans to resolve cold storage issues in India

Rediff.com   7 Dec 2020

The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring. Sohini Das and Ruchika Chitravanshi report.

Sale of Reliance Capital's assets gets resounding response

Sale of Reliance Capital's assets gets resounding response

Rediff.com   3 Dec 2020

Blackstone, KKR, and Bain Capital, among others, are in the race for its general insurance arm, and Bandhan Bank, Bain, and Dabur Investments have shown interest for RCap's 51 per cent stake in the life insurance business.

From January, consumer goods are likely to cost more by 3-5%

From January, consumer goods are likely to cost more by 3-5%

Rediff.com   3 Dec 2020

Prices of all metals - from steel to copper, aluminium, zinc and lead - have shot up by about 5-11 per cent in the past month. Commodity inflation is raising its head, forcing companies to consider price hikes.

How states are preparing for Covid vaccine distribution

How states are preparing for Covid vaccine distribution

Rediff.com   2 Dec 2020

Each state has its own weak areas that need attention. Some states have already identified the gaps and sought the Centre's help. Vinay Umarji, Ishita Ayan Dutt, Samreen Ahmad and Sohini Das report.

Tata, Birla, Bajaj, and Piramal Group may lead race for bank licence

Tata, Birla, Bajaj, and Piramal Group may lead race for bank licence

Rediff.com   1 Dec 2020

NBFCs with a proven track record, supported by the brand values of reputed corporate, can play a key role in bringing the benefits of banking and economy to the underserved and newer segments of India.

India may get first Covid-19 vaccine by February

India may get first Covid-19 vaccine by February

Rediff.com   30 Nov 2020

The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das.

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Rediff.com   26 Nov 2020

The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation.

Peeved Piramal says will quit race for DHFL over Adani's 11th-hour bid

Peeved Piramal says will quit race for DHFL over Adani's 11th-hour bid

Rediff.com   17 Nov 2020

Adani, which had earlier bid only for the wholesale book, now want all of DHFL's assets and has pipped both Oaktree and Piramal by bidding higher than each of them.

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Rediff.com   13 Nov 2020

'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'

Sops, stamp duty cut help home sales in Mumbai surge

Sops, stamp duty cut help home sales in Mumbai surge

Rediff.com   5 Nov 2020

Mumbai Metropolitan Region recorded housing sales of nearly 9,200 units in Q3 of calender 2020, against 3,620 units in the preceding quarter, registering a 1.5 times growth which is the highest growth seen any city except Chennai.

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Rediff.com   4 Nov 2020

Siemens Healthineers, one of the largest manufacturers of made-in-India CT scanners, has sold 80-100 such machines in the last 45 days. The medical technology firm typically sells 250 machines in a year.

Bharat Biotech starts Covaxin's at-risk manufacture

Bharat Biotech starts Covaxin's at-risk manufacture

Rediff.com   2 Nov 2020

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com   25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

Covid-19: Zero cash flows force India Inc to sell assets

Covid-19: Zero cash flows force India Inc to sell assets

Rediff.com   22 Oct 2020

Not just mid- and small-sized firms, even big ones will either sell group companies or stakes in their listed entities to tide over crisis; more sell-offs seen in coming months.

Singapore's Mapletree Investments buys land in Mumbai for Rs 525 crore

Singapore's Mapletree Investments buys land in Mumbai for Rs 525 crore

Rediff.com   12 Oct 2020

The Kanakia group, from which Mapletree did the purchase, had bought the plot from India Tube Mills and Metal Industries for Rs 363 crore in 2018.

Covid-19 impact: Low interest loans likely for vaccine companies

Covid-19 impact: Low interest loans likely for vaccine companies

Rediff.com   10 Oct 2020

While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.

Will PNB acquire beleaguered Lakshmi Vilas Bank?

Will PNB acquire beleaguered Lakshmi Vilas Bank?

Rediff.com   8 Oct 2020

PNB has rich experience in the integration of commercial banks.

Fuelled by demand in southern markets, office leasing rises

Fuelled by demand in southern markets, office leasing rises

Rediff.com   6 Oct 2020

The Q3 office rebound growth was led by Bengaluru and Hyderabad, which together accounted for nearly 80 per cent of the net absorption in Q3.

Covaxin: How Bharat Biotech plans to boost immunity

Covaxin: How Bharat Biotech plans to boost immunity

Rediff.com   6 Oct 2020

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed.

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Rediff.com   6 Oct 2020

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.